Skip to main content

Table 2 Estimated effect size for neurodevelopmental outcome (survival at 2 years without moderate/severe neurodevelopmental impairment) for anticipated questionnaire returns

From: Follow-up study of infants recruited to the randomised, placebo-controlled trial of azithromycin for the prevention of chronic lung disease of prematurity in preterm infants—study protocol for the AZTEC-FU study

Size per group

Survival without moderate/severe neurodevelopmental impairment

Detectable effect size

Power 0.8, alpha 0.05, initial incidence of survival without moderate/severe neurodevelopmental impairment of 50%

 350

60.7%

10.7%

 300

61.6%

11.6%

 250

62.7%

12.7%

 200

64.4%

14.6%

Power 0.9, alpha 0.05, initial incidence of survival without moderate/severe neurodevelopmental impairment of 50%

 350

62.3%

12.3%

 300

63.3%

12.3%

 250

64.6%

14.6%

 200

66.4%

16.4%